<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04850638</url>
  </required_header>
  <id_info>
    <org_study_id>SHR4640-108</org_study_id>
    <nct_id>NCT04850638</nct_id>
  </id_info>
  <brief_title>Drug Interaction Between SHR4640 Tablets and Furosemide Tablets in Healthy Volunteers (Single Center, Single Arm, Open, Self-control)</brief_title>
  <official_title>Drug Interaction Between SHR4640 Tablets and Furosemide Tablets in Healthy Volunteers (Single Center, Single Arm, Open, Self-control)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the effect of SHR4640 tablets on the&#xD;
      pharmacokinetics of furosemide tablets in healthy male volunteers, using a single-center,&#xD;
      single-arm, open, self-control design.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 28, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day1 to Day10</time_frame>
    <description>Peak plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>Day1 to Day10</time_frame>
    <description>Area under the curve from the time of dosing. Dosing time to the last measurable (positive) concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf (if available)</measure>
    <time_frame>Day1 to Day10</time_frame>
    <description>Area under the curve from time 0 to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ae</measure>
    <time_frame>Day1 to Day10</time_frame>
    <description>Cumulative Amount of excretion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CLr</measure>
    <time_frame>Day1 to Day10</time_frame>
    <description>Renal Clearance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Day1 to Day10</time_frame>
    <description>Half time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Day1 to Day10</time_frame>
    <description>Time of maximum observed concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>Day1 to Day10</time_frame>
    <description>apparent clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F</measure>
    <time_frame>Day1 to Day10</time_frame>
    <description>apparent volume of distribution</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Healthy Male Subjects</condition>
  <arm_group>
    <arm_group_label>SHR4640 tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR4640 tablets and furosemide tablets</intervention_name>
    <description>SHR4640 tablets and furosemide tablets</description>
    <arm_group_label>SHR4640 tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntarily sign the informed consent form before the start of the activities related&#xD;
             to this trial, and be able to understand the procedures and methods of this trial, and&#xD;
             be willing to strictly abide by the clinical trial plan to complete this trial;&#xD;
&#xD;
          2. Adult males aged between 18 and 45 (including both ends, whichever is the time of&#xD;
             signing the informed consent form);&#xD;
&#xD;
          3. Body weight ≥ 50kg and body mass index (BMI): 19~26kg/m2 (including both ends).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have a fertility plan or refuse to use medically approved contraceptives within 1&#xD;
             month from the screening period to the last medication;&#xD;
&#xD;
          2. Smokers (those who smoke more than 5 cigarettes per day on average);&#xD;
&#xD;
          3. During the first month of screening, the average daily alcohol intake was more than&#xD;
             25g (for example, 750mL beer, 250mL wine, or 50mL liquor) or those who were positive&#xD;
             for alcohol in blood test or alcohol breath test during screening;&#xD;
&#xD;
          4. Those who have eaten grapefruit or its fruit juice products, any caffeine (such as&#xD;
             coffee, tea, chocolate, cola or other caffeinated carbonated drinks, etc.), alcoholic&#xD;
             food or beverages within 2 days before administration;&#xD;
&#xD;
          5. Drug abusers or those who were positive in urine drug test during screening;&#xD;
&#xD;
          6. The researchers judged that the subjects had medical conditions that affected the&#xD;
             absorption, distribution, metabolism and excretion of drugs or reduced compliance&#xD;
&#xD;
          7. Any clinical history of serious illness or any disease or condition that the&#xD;
             researchers believe may affect the results of the trial, including, but not limited&#xD;
             to, a history of circulatory, endocrine, nervous system, digestive, urinary or blood,&#xD;
             immune, mental and metabolic diseases;&#xD;
&#xD;
          8. Allergic constitution, or allergic to any ingredient in SHR4640 and furosemide&#xD;
             tablets, or allergic to sulfonamides or thiazide diuretics, or allergic to any food&#xD;
             ingredient, or having special dietary requirements, unable to follow a uniform diet;&#xD;
&#xD;
          9. Previous history of urinary diseases (such as benign prostatic hyperplasia, urinary&#xD;
             tract stenosis) or other diseases that lead to dysuria;&#xD;
&#xD;
         10. Screen those who have undergone any operation within the first 3 months, or who have&#xD;
             not recovered after the operation, or who may have a plan for operation or&#xD;
             hospitalization during the trial;&#xD;
&#xD;
         11. Those who donated blood (or lost blood) and donated blood (or lost blood) ≥ 400 mL&#xD;
             within 3 months before screening, or received blood transfusion;&#xD;
&#xD;
         12. During screening, physical examination, vital signs, laboratory examination (whole&#xD;
             blood cell analysis, blood biochemical analysis, blood electrolyte examination, urine&#xD;
             analysis, fasting blood lipids, thyroid function), 12-lead ECG, X-chest X-ray and&#xD;
             abdominal B-ultrasound were abnormal and had clinical significance.&#xD;
&#xD;
         13. When screening, systolic blood pressure was less than 90mmHg or greater than 140mmHg,&#xD;
             and / or diastolic blood pressure was less than 60mmHg or greater than 90mmHg;&#xD;
&#xD;
         14. Urinary system ultrasound suggested or suspected urinary system crystals or stones&#xD;
             during screening;&#xD;
&#xD;
         15. Those whose serum uric acid was higher than 420 μ mol / L or had a previous history of&#xD;
             hyperuricemia and / or gout;&#xD;
&#xD;
         16. The level of serum potassium was lower than that of 4.0mmol/L during screening.&#xD;
&#xD;
         17. According to the serum creatinine within 2 weeks before administration, the glomerular&#xD;
             filtration rate ((estimated glomerular filtration rate, eGFR) calculated by the&#xD;
             simplified kidney disease diet adjustment (modification of diet in renal disease,&#xD;
             MDRD) formula (Annex 1) is less than 90 mL/min/1.73 m ².&#xD;
&#xD;
         18. Those who were positive for hepatitis B surface antigen (HBsAg), or anti-hepatitis C&#xD;
             virus (HCV) antibody, or human immunodeficiency virus (HIV) antibody, or syphilis&#xD;
             antibody within one month before the screening;&#xD;
&#xD;
         19. Screening people who have participated in any drug or medical device clinical trial&#xD;
             within the previous 3 months (subject to signing informed consent);&#xD;
&#xD;
         20. Used any prescription drugs, over-the-counter drugs, Chinese herbal medicines or&#xD;
             dietary supplements within 2 weeks before screening.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xuechao Song</last_name>
    <phone>+86 18036618571</phone>
    <email>songxuechao@hrglobe.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ping Feng, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2021</study_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

